Literature DB >> 10624765

Helicobacter pylori and upper gastrointestinal symptoms in bronchiectasis.

K W Tsang1, W K Lam, E Kwok, K N Chan, W H Hu, G C Ooi, L Zheng, B C Wong, S K Lam.   

Abstract

The recently reported increase in seroprevalence of Helicobacter pylori, the causative pathogen in peptic ulceration, in bronchiectasis is unexplained. Therefore, the association of antibodies directed against cytotoxin-associated gene A(CagA), whose expression indicates virulence of H. pylori, and upper gastrointestinal symptoms in patients with stable bronchiectasis and healthy volunteers evaluated. One hundred patients (mean +/- SD age 55.1+/-16.7 yrs) and 94 healthy asymptomatic subjects (54.6+/-7.6 yrs) underwent clinical and physiological assessment and serum levels of anti-H. pylori CagA were determined using standard clinical and enzyme-linked immunosorbent assay techniques. Samples were positive for anti-H. pylori CagA in 11.7% of controls and 24% of bronchiectatic subjects (p = 0.03). There was, however, no association between serum H. pylori CagA immunoglobulin G level and forced expiratory volume in one second (FEV1), forced vital capacity (FVC), sputum volume, respiratory symptoms or upper respiratory gastrointestinal symptoms (p>0.05). Patients who suffered from acid regurgitation or upper abdominal distension had significantly lower FEV1 and FVC (as a percentage of the predicted value) compared to their counterparts. The results of anticytotoxin-associated gene A measurements in this study contrasted with the previous finding that anti-Helicobacter pylori immunoglobulin G correlated with sputum volume. These findings, therefore, suggest that Helicobacter pylori, should it have a pathogenic role in bronchiectasis, could act via noncytotoxin-associated gene A-mediated mechanisms, and, in this context, gastro-oesophageal reflux might be of importance in bronchiectasis.

Entities:  

Mesh:

Substances:

Year:  1999        PMID: 10624765     DOI: 10.1183/09031936.99.14613459

Source DB:  PubMed          Journal:  Eur Respir J        ISSN: 0903-1936            Impact factor:   16.671


  4 in total

1.  Construction and characterization of bivalent vaccine candidate expressing HspA and M(r)18,000 OMP from Helicobacter pylori.

Authors:  Zheng Jiang; Ai-Long Huang; Xiao-Hong Tao; Pi-Long Wang
Journal:  World J Gastroenterol       Date:  2003-08       Impact factor: 5.742

2.  Neutrophil apoptosis, proinflammatory mediators and cell counts in bronchiectasis.

Authors:  A P Watt; V Brown; J Courtney; M Kelly; L Garske; J S Elborn; M Ennis
Journal:  Thorax       Date:  2004-03       Impact factor: 9.139

3.  Gastro-oesophageal reflux in noncystic fibrosis bronchiectasis.

Authors:  Annemarie L Lee; Brenda M Button; Linda Denehy; John W Wilson
Journal:  Pulm Med       Date:  2011-11-10

4.  Gastroesophageal reflux in bronchiectasis and the effect of anti-reflux treatment.

Authors:  Zhi-Wei Hu; Zhong-Gao Wang; Yu Zhang; Ji-Min Wu; Jian-Jun Liu; Fang-Fang Lu; Guang-Chang Zhu; Wei-Tao Liang
Journal:  BMC Pulm Med       Date:  2013-06-03       Impact factor: 3.317

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.